In multiple myeloma (MM), miR-17 is also oncogenic and affects iron transport by regulating Ferroportin 1 (FPN1), in which decreased FPN1 levels leads to MM cell growth and proliferation and also correlates with bad prognosis [75]. This evidence concerns the gene SLC40A1 and Miyoshi myopathy.